STILLTRACE

What is STILLTRACE?

Imagine a tower defense game where you're actually terrified to leave your base. STILLTRACE drops you into a bleak, infected wasteland where you're the last person guarding a beacon against a tide of horrors.

Gameplay

You're not just sitting back and watching towers do the work here. In STILLTRACE, you're holding down the last beacon in an infected sector, and the loop is all about risk. You've gotta leave your fortifications to scavenge for ammo, meds, and parts in a bleak wasteland. It's that constant stress of deciding if you can grab one more piece of loot or if you need to hustle back before the wave hits. Once you're home, you spend your time fortifying with mines and turrets to keep the creeps away.

If you're coming from something like Bloons TD, forget the colorful chaos. This is a gritty survival sim hybrid. The atmosphere is heavy, and the horror elements actually make the defense part feel high-stakes because you're genuinely scared of losing your gear. It's more about desperation than total domination, which means the pacing can feel a bit slow if you're just itching to build massive armies of guns.

At $6.99, it's a fair price for an indie project, but you'll notice the rough edges. It's early days for this one, and it definitely feels like an indie effort. You aren't getting a polished masterpiece, but you are getting a unique vibe that blends base defense with a top-down horror experience. I'd give it a 7/10 for trying something different with the genre.

Key Features

• Scavenge for ammo and meds
• Fortify beacon with turrets and mines
• Top-down survival horror atmosphere
• Follow strange radio calls and tracks

Video Review

Screenshots

Verdict

Grab this if you love anxious, atmospheric survival games that challenge your nerves. If you prefer cozy, high-power fantasy or fast-paced building, skip this one or wait until the pacing is polished.

* Price at time of publication (checked 16.09.2026). Prices may vary by region and are subject to change. This is an editorial review, not a commercial offer.